Letters and medicine recalls sent to healthcare professionals in July 2024. A simvastatin, rosuvastatin and pitavastatin (singl Therapeutic area
The last Recall Enforcement Report for Rosuvastatin with NDC was initiated on as a Class II recall due to cgmp deviations: recalling drug products following an fda inspection.
2024 regarding medical devices recall and Field Safety Corrective Actions rosuvastatin) and pharmaceutical products that contains (amlodipine/ rosuvastatin).
Subject: Recalls, Market Withdrawals Safety Alerts, Jan 2024 to Mar 2024 Rosuvastatin Tablets, USP, 5 mg, Rx Only.
In September 2024, recalls and notifications for medicines were issued on: Class 4 Medicines Defect Information, Rosuvastatin 5 mg, 10 mg
The last Recall Enforcement Report for Rosuvastatin with NDC was initiated on as a Class II recall and it is currently terminated.
by SM Wolfe 2024 Cited by 100rosuvastatin be withdrawn from the market? Lancet. 20 Pressure group urges rosuvastatin recall. Ault A Lancet, 363(9412):
Letters and medicine recalls sent to healthcare professionals in July 2024. A rosuvastatin and pitavastatin (singl Therapeutic area: Cardiovascular
The last Recall Enforcement Report for Rosuvastatin with NDC was initiated on as a Class II recall due to cgmp deviations: recalling drug products following an fda inspection. The latest recall number for this product is D- and the recall is currently terminated as of . Recall Number.
Comments